exchange gain/(loss) (0.35) 0.32 -191.43% Other income 2.36 3.11 31.78% Earnings before interest and taxes 64.97 237.44 265.46% Financial expense (2.30) (2.31) 0.43% Profit before income tax expense 62.67
baht, an increase of 141.55 million baht or 16.27%. For the impairment loss of loans was 193.53 million baht, a decrease of 209.07 million baht or 51.93%. Financial Position Overview As of 31 December
affected of long-term employment benefits of 400 days scheme increasing of Baht 26.00 million and account payable of Baht 41.41 million. The shareholders' equity decreased by 15.17% resulting from the loss
250.00% Net foreign exchange gain/(loss) 0.32 0.93 190.63% Other income 3.11 5.87 88.75% Earnings before interest and taxes 237.44 124.30 -47.65% Financial expense (2.31) (1.86) -19.48% Profit before
service agreement between Solvay and AGC, plus higher transportation costs from export sales portion. 3. In Q2 2017, the Company and its subsidiaries recorded additional impairment loss from the liquidation
30.00M and return loan from UOB Baht 12.00M. The equity’s shareholder was lower than last year at 1.69% due operating loss this previous. - Came from invested on Sahaphat Amorn Company Limited for develop
personal loan at Baht 30.00M and return loan from UOB Baht 12.00M. The equity’s shareholder was lower than last year at 1.69% due operating loss this previous. - Came from invested on Sahaphat Amorn Company
greater export sales portion. 3. In Q3 2017, the Company and its subsidiaries recorded the assets’ impairment loss and write- off of Solvay Biochemicals (Taixing) Limited (“SBT”) net amounting to 132 MB
according to Thai Accounting standard No.12 “Income tax”. However as at 30 September 2017, the Company still has retained deficit to be applied within 5 years from the loss year in the amount of 19.39 million
return loan from UOB Baht 12.00M., Credit term extension with vendors. The equity’s shareholder was lower than last year at 5.49% due operating loss this year. - In order to effectively manage the sales